Kamada (NASDAQ:KMDA) Cut to “Buy” at StockNews.com

StockNews.com cut shares of Kamada (NASDAQ:KMDA) from a strong-buy rating to a buy rating in a research note published on Tuesday.

A number of other research firms have also weighed in on KMDA. Stifel Nicolaus started coverage on Kamada in a research note on Wednesday, July 3rd. They issued a buy rating and a $18.00 target price on the stock. HC Wainwright reaffirmed a buy rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, August 15th.

Kamada Stock Performance

KMDA opened at $5.80 on Tuesday. Kamada has a one year low of $4.08 and a one year high of $6.53. The stock has a market cap of $333.38 million, a price-to-earnings ratio of 25.22 and a beta of 1.06. The stock’s 50 day moving average price is $5.54 and its 200-day moving average price is $5.55.

Hedge Funds Weigh In On Kamada

Hedge funds and other institutional investors have recently made changes to their positions in the company. Calton & Associates Inc. bought a new stake in shares of Kamada in the fourth quarter valued at about $111,000. Y.D. More Investments Ltd raised its holdings in shares of Kamada by 107.1% in the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 15,000 shares in the last quarter. Aristides Capital LLC lifted its position in shares of Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 16,635 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares during the period. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.